Gsk Share Discussion Threads

[barbel3] 23/11/2018 16:40

hi guys so if the dollar drops to the pound does that mean its better for gsk share price just out of interest cheers

[tradermichael] 23/11/2018 11:26

£1 = $1.28

[tradermichael] 22/11/2018 10:46

The now better tone in the Sterling is pushing Cable to fresh multi-day peaks in the area above 1.2900 the figure on Thursday, up more than a cent from daily lows in the 1.2770 zone.
In fact, the Sterling grabs extra buying interest after the publication of a leaked Brexit deal draft. The leaked draft says the UK commits to align with EU rules on trade of goods, while both parties could consider technological solutions to prevent the ‘hard border’.
In addition, the draft also sees the probability that the ‘transition period’ could be extended for up to 1 or 2 years.

[alphorn] 22/11/2018 10:41

Sharp GBP move upwards re (apparent) leaked Brexit document.

[tradermichael] 22/11/2018 10:07

LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday it has signed a strategic commercialisation deal for its anaemia drug Daprodustat with Japanese firm Hakko Kirin Co Ltd.
Financial details of the Japanese commercialisation deal have not been disclosed.
Pharma heavyweight GSK will be responsible for completing the ongoing phase three clinical programme and regulatory submissions required to achieve marketing authorisation in Japan
Life sciences company Hakko Kirin will then distribute Daprodustat to the Japanese market on an exclusive basis.
Hakko Kirin and GSK will jointly conduct launch activities, such as healthcare professional engagement.
Daprodustat is used to treat anaemia in patients with chronic kidney disease, who are more prone to anaemia. Symptoms of patients with anaemia associated with chronic kidney disease include palpitation, dizziness, fatigue, and shortness of breath.
Daprodustat is not currently approved as an anaemia treatment in chronic kidney disease patients or for any other indication. However, positive results from two phase three studies in kidney dialysis patients were recently announced.
In addition, results from a final phase three Japanese study of patients who are not dependent on dialysis are expected in the first half of 2019.
A global phase three registration programme for Daprodustat in anaemic kidney disease patients is ongoing. This includes the Ascend-D trial, which will enrol roughly 3,000 dialysis-dependent patients, and Ascend-ND trial which will enrol approximately 4,500 non-dialysis patients.

[nik rosa] 22/11/2018 09:02

TM, I see what you are saying but I feel the trend line is only in a positive direction because of that one-off major dip in October (which soon recovered).
Please note, I have amended my typo in my previous post; no-one should be selling at 1500!! N.R.

[tradermichael] 21/11/2018 15:00

nik - no chartist me, but I've been referring to the bigger pattern that started early September ….. ;0)

[sicker] 21/11/2018 14:42

Another assault on £16.00 repulsed, surely can't be long now :-)

[nik rosa] 21/11/2018 14:25

The recent inverse "shoulder" was at c1500. I would expect another drop to an inverse "head" after that. However, I will be thinking to sell at 1600 unless Horlicks gives a spike. Never used to be a chartist, but GSK has become somewhat predictable. GL NR

[tradermichael] 21/11/2018 09:50

NY B - it looks like your inverse head and shoulders is playing out nicely. Any projections on where the chart would peak?

[warranty] 20/11/2018 20:35

Just need to get past the 1600p level for this to really run.

[tim 3] 20/11/2018 12:58

Definitely performing better relative to the FTSE recently.

[ny boy] 20/11/2018 11:48

Safe haven characteristics showing now.

In times of turmoil, park cash in multi national blue chip plays imo

[davemac3] 20/11/2018 09:18

can't get past £15.80

[tradermichael] 19/11/2018 15:44

GlaxoSmithKline PLC (GSK.LN) said Monday that it is looking to expand the indication for its Nucala medicine--an add-on treatment for severe eosinophilic asthma--to include children aged six to 11 in the U.S.
The pharmaceutical company said that it has filed a supplemental biologics license application with the Food and Drug administration to expand the indication to include the lower age group.
In Europe, Nucala is available for children aged six to 17 years old, as well as adults, GlaxoSmithKline said.

[fangorn2] 19/11/2018 12:44

European advisory group backs ViiV Healthcare's Tivicay + lamivudine in HIV-1

[tradermichael] 19/11/2018 08:22

Food and beverages giant Nestle will go up against Unilever in the final round of negotiations for GlaxoSmithKline̵7;s (GSK) consumer nutrition business in India, as the third shortlisted contender Coco-Cola has dropped out of the race, according to a report by The Economic Times.
The bids for GSK's stake in the business will likely be between $3.1 billion and $3.5 billion, sources told the newspaper. Whichever company successfully buys the stake will have to buy an additional 26 percent through an open offer.

[zho] 15/11/2018 10:02

That's sterling plunging on Raab and McVey resignations

[sicker] 15/11/2018 09:47

what a pleasant ex div surprise :-)

[toffeeman] 14/11/2018 17:44

Neckline test

[jadeticl3] 14/11/2018 17:23

Let’s hope that this was the drop for XDDay!

[nico9] 14/11/2018 16:16

Lets just hope that the drop on XD day isn't worse than the drop today!!

[jadeticl3] 14/11/2018 14:07

Everything is up this afternoon—R12;well nearly everything!!!

[porsche1945] 14/11/2018 13:28

wish id dumped this and stuck with astra, went the other way, its a dividend play but worse than useless for capital growth, market just doesnt believe in this company and it needs breaking up and the value extracting, id rather have a fast 30 pc uplift in share price then put the money to work elsewhere.

[tradermichael] 14/11/2018 11:08

Yes, tomorrow